The answer is no, these are not equivalent products. Unlike potassium chloride, potassium citrate does not have an FDA-approved labeled indication for the treatment of hypokalemia. Potassium citrate's three indications are as follows:
- Prevention of uric acid nephrolithiasis
- Prevention of calcium renal stones in patients with hypocitraturia
- Urinary alkalinizer for situations in which sodium citrate is contraindicated
Mechanism of Action:
Oral administration of potassium citrate produces an alkaline load, as the citrate is converted hepatically to bicarbonate. This increases the urinary pH and further enhances the clearance of citrate, thus increasing urine citrate concentration. Also, the bicarbonate may reduce bone resorption (release of calcium from bone to blood via action of osteoclasts) and increased renal calcium reabsorption. These combined effects may lead to a transient decrease in urinary calcium, and makes the environment of the urine less conducive to the crystallization of stone-forming salts. Increased urinary PH also causes uric acid's more soluble urate ion to form, thus decreasing the risk of uric acid stones.
GENERIC
|
DOSAGE FORM
|
BRAND NAMES
|
AVAILABLE STRENGTHS
|
INDICATIONS
|
Potassium Chloride
|
Extended-release capsules
|
Micro-K
|
8 mEq; 10 mEq
|
· Treatment/prevention of hypokalemia
***K-TAB NOT BIOEQUIVALENT |
Oral Solution
|
K-Sol
|
20 mEq/15 mL ; 40 mEq/15mL
| ||
Oral packet
|
K-Vescent
|
20 mEq
| ||
Klor-Con
|
20 mEq; 25 mEq
| |||
Extended-release tablets
|
K-Tab
|
8 mEq; 10 mEq; 20 mEq
| ||
Klor-Con
|
8 mEq; 10 mEq; 15 mEq; 20 mEq
| |||
Potassium Citrate
|
Extended release tablets
|
Urocit-K 5
|
5 mEq
|
· Prevention of uric acid nephrolithiasis
· Prevention of calcium renal stones in patients with hypocitraturia
· Urinary alkalinizer when Na-Citrate contraindicated
|
Urocit-K 10
|
10 mEq
| |||
Urocit-K 15
|
15 mEq
| |||
Potassium Gluconate
(1gm = 4.3 mEq) |
Capsules
|
K-99
|
595 mg
|
· Dietary supplement
|
Tablets
|
(generic)
|
2 mEq; 2.5 mEq; 8mg (base)
| ||
Potassium Acid Phosphate
(500mg = 3.7 mEq)
|
Tablets
|
K-Phos
|
500mg
|
· Acidify urine—lower urine calcium concentration
· Reduce odor and rash from ammonia in urine
· Synergistic effect with antibacterial activity of methenamine
|
Potassium Bicarbonate/Potassium Citrate
|
Tablets (for solution)
|
Effer-K
|
10 mEq; 20 mEq
|
· Treatment/prevention of hypokalemia (if avoiding chloride or acid/base status requiring bicarb)
|
Klor-Con/EF
|
25 mEq
| |||
Potassium Iodide
|
Oral Solution
|
SSKI
|
1 gm/mL
|
· Expectorant; chronic pulmonary diseases complicated by mucus
· Block uptake of radioactive isotopes
|
ThyroShield
|
65 mg/mL
| |||
Potassium
P-aminobenzoate
|
Capsules
|
M2 Potassium
|
60 mg
|
· Scleroderma
· Dermatomyositis
· Morphea
· Pemphigus
· Peyronie’s Disease
|
Potaba
|
500 mg
| |||
Packet
|
(generic)
|
2g
| ||
Tablets
|
Potaba
|
500 mg
|
References:
1. Lexicomp. Accessed 7/31/2015. <www.online.lexi.com.proxy.lib.uiowa.edu>
2. Drugs.com. Accessed 7/31/2015 <http://www.drugs.com/pro/potassium-citrate.html>
3. Krieger NS, Asplin JR, Frick KK, et al. Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria. J Am Soc Nephrol. 2015.
Had a very good customer service and good staff behaviour and on time delivery of medicine. Very good. Online Pharmacy
ReplyDelete